SPORADIC MEDULLARY THYROID CANCER. СASE REPORT
https://doi.org/10.17650/2222-1468-2014-0-3-51-56
Abstract
The histologic picture of the medullary cancer can resemble a papillary and follicular cancer that takes away doctors towards the wrong statement of the diagnosis. Therefore it is necessary to investigate calcitonin in the presence of knot in a thyroid gland. Research on existence of mutation RET-protoonkogen is obligatory for an exception of hereditary forms of the medullary cancer. Research of time of doubling of calcitonin in the postoperative period allows to predict survival of patients. Bisfosfonates interfere with progressing of metastatic process at the medullary cancer of the thyroid gland.
About the Authors
L. A. Ivanova
Kuban State Medical University, Krasnodar
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
A. N. Pakhomova
Kuban State Medical University, Krasnodar
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
Yu. M. Gavrilova
Kuban State Medical University, Krasnodar
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
A. S. Klimova
Kuban State Medical University, Krasnodar
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
O. N. Rostovtseva
Kuban State Medical University, Krasnodar
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
Russian Federation
Department of Endocrinology, Faculty for Advanced Training and Professional Retraining of Specialists
References
1. Газизова Д. О., Бельцевич Д. Г. Современный взгляд на проблему диагностики и лечения медуллярного рака щитовидной железы. Эндокринная хирургия 2013;3:4–21.
2. Абдулхабирова Ф. М., Бельцевич Д. Г., Ванушко В. Э. и др. Диагностика и лечение медуллярного рака щитовидной железы (Проект национальных клинических рекомендаций). Эндокринная хирургия 2012;1:5–17.
3. Lam E. T., Ringel M. D., Kloos R. T. Anti-tumor activity of Sorafenib in patients with metastatic medullary thyroid carcinoma. Proceedings of the American Association for Cancer Research 2009. Abstract 4513.
4. Papewalis C., Wuttke M., Seissler J. et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res 2008;14(13):4298–305.
5. Robinson B. G., Paz-Ares L., Krebs A. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6): 2664–71.
6. Salgia R., Sherman S., Hong D. S. et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008;26: Abstract 3522.
7. Wells S. A. Jr, Gosnell J. E., Gagel R. F. et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. ASCO Annual Meeting Proceedings Part I 2007;25:6016.
8. Wells S. A. Jr, Robinson B. G., Gagel R. F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double_blind phase III trial. J Clin Oncol 2012;30(2):134–41.
9. Wells S., Gosnell J., Gagel R. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medul lary thyroid cancer. J Clin Oncol 2010;28(5): 767–72. doi: 10.1200 / JCO. 2009.23.6604.
10. Xu L., Wang W. B., Zhao Y. P. et al. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis. J Surg Oncol 2012;106(2): 169–73.
Review
For citations:
Ivanova L.A., Pakhomova A.N., Gavrilova Yu.M., Klimova A.S., Rostovtseva O.N. SPORADIC MEDULLARY THYROID CANCER. СASE REPORT. Head and Neck Tumors (HNT). 2014;(3):51-56. (In Russ.) https://doi.org/10.17650/2222-1468-2014-0-3-51-56
Views:
1293
Email this article 